SK
Sumanth Karlapudi
About Sumanth Karlapudi
Data last updated:
Sumanth Karlapudi is a Director at Krebs Biochemicals And Industries Limited (since 2025), Director at Phanicare Pharmaceuticals Private Limited (since 2022) and Director at Norrish Laboratories Private Limited (since 2023), and holds 1 more current directorship. The companies operate in Life Sciences, Pharma and Information Technology. The 3 current companies with reported revenue have a combined latest revenue of ₹106 Cr; the largest is Krebs Biochemicals And Industries Limited at ₹44.02 Cr (FY 2025).
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
| Director | 04 Feb 2025 | 1991 | ₹44.02 Cr (FY 2025) | Active | |
| Director | 01 Oct 2022 | 2003 | ₹41.70 Cr (FY 2024) | Active | |
| Director | 22 Sep 2023 | 2012 | ₹20.76 Cr (FY 2024) | Active | |
| Director | 29 May 2021 | 2021 | Active |
Board colleagues of Sumanth Karlapudi
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Sumanth Karlapudi
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Sumanth Karlapudi
Sumanth Karlapudi currently holds 4 directorships: Krebs Biochemicals And Industries Limited (Director, since 04 Feb 2025, revenue ₹44.02 Cr (FY 2025)); Phanicare Pharmaceuticals Private Limited (Director, since 01 Oct 2022, revenue ₹41.70 Cr (FY 2024)); Norrish Laboratories Private Limited (Director, since 22 Sep 2023, revenue ₹20.76 Cr (FY 2024)); Profield Organics Private Limited (Director, since 29 May 2021).
Sumanth Karlapudi was first appointed on 29 May 2021 as Director at Profield Organics Private Limited. The most recent appointment on record is 04 Feb 2025 at Krebs Biochemicals And Industries Limited.
The 3 current companies of Sumanth Karlapudi that report revenue have a combined latest revenue of ₹106 Cr: Krebs Biochemicals And Industries Limited ₹44.02 Cr (FY 2025); Phanicare Pharmaceuticals Private Limited ₹41.70 Cr (FY 2024); Norrish Laboratories Private Limited ₹20.76 Cr (FY 2024).
The current boards of Sumanth Karlapudi's companies include Avinash Ravi (Krebs Biochemicals And Industries Limited), Dipti Chinubhai Shah (Krebs Biochemicals And Industries Limited), Manish Kumar Jain (Krebs Biochemicals And Industries Limited), Manish Kumar Jain (Krebs Biochemicals And Industries Limited), Pabitrakumar Kalipada Bhattacharyya (Krebs Biochemicals And Industries Limited), Popatlal Mukanchand Kathariya (Krebs Biochemicals And Industries Limited), among others.